病例报告 : EGFR - TKI 治疗后同步多原发肺癌患者的不同耐药机制。
关键词: MET amplification T790 M mutation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistance mechanism synchronous multiple primary lung cancer (SMPLC) MET amplification T790 M mutation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) resistance mechanism synchronous multiple primary lung cancer (SMPLC)
来 源:
DOI:10.3389/fonc.2022.977065
PDF(Pubmed)